NCT04000906View on ClinicalTrials.gov

PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 11, 2020

Primary Completion Date

December 12, 2023

Study Completion Date

December 31, 2024

Conditions
Peritoneal Carcinomatosis
Interventions
DRUG

Nab paclitaxel

Dose escalation (7.5 mg/m2, 15 mg/m2, 25 mg/m2, 37.5 mg/m2, 52.5 mg/m2 and 70 mg/m2)

DRUG

Cisplatin

10.5 mg/m2

Trial Locations (2)

1011

University Hospital, Lausanne, Lausanne

1211

University Hospital, Geneva, Geneva

All Listed Sponsors
lead

University Hospital, Geneva

OTHER

NCT04000906 - PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis | Biotech Hunter | Biotech Hunter